EUCTR2005-000174-52-IT
Active, Not Recruiting
N/A
Phase II multicenter study of immuno-chemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) for symptomatic Waldenstrom's macroglobulinemia
ASSOCIAZIONE MALATTIE SANGUE0 sitesDecember 11, 2007
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- ASSOCIAZIONE MALATTIE SANGUE
- Status
- Active, Not Recruiting
- Last Updated
- 12 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, Not Recruiting
N/A
Patients who suffer from T-Prolymphocytic leukemia and have received none or one chemotherapy so far will be treated with Fludarabine, Cyclophosphamide, Mitoxantrone and Alemtuzumab.ntreated patients with T-prolymphocytic leukemia (T-PLL) according to WHO criteria or pretreated patients (max. one previous treatment) with T-PLL .Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2008-001421-34-DEniversity of Cologne, Sponsor-Quality Management16
Active, Not Recruiting
N/A
Patients who suffer from T-Prolymphocytic leukemia and have received none or one chemotherapy so far will be treated with Fludarabine, Cyclophosphamide, Mitoxantrone and Alemtuzumab.ntreated patients with T-prolymphocytic leukemia (T-PLL) according to WHO criteria or pretreated patients (max. one previous treatment) with T-PLL.Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2008-001421-34-ATniversität zu Köln16
Recruiting
N/A
Randomized phase II study of chemoimmunotherapy with or without metformin as a first-line treatment in patients with squamous cell lung carcinomaNeoplasmsKCT0008659ational Cancer Center70
Active, Not Recruiting
N/A
PHASE II TRIAL OF SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH CAPECITABINE PLUS INTERFERON ALPHA2a FOLLOWED BY IL-2 IN PATIENTS WITH METASTATIC KIDNEY CANCEREUCTR2004-002376-42-ITG.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST36
Active, Not Recruiting
Phase 1
A randomized phase 2 study comparing immunotherapy with chemotherapy in the treatment of elderly patients with advanced NSCLCpatients with advanced NSCLCMedDRA version: 20.0Level: LLTClassification code 10001160Term: Adenocarcinoma lungSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-001664-37-ITISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE240